Outcomes of Older Women With Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor–Negative Metastatic Breast Cancer Treated With a CDK4/6 Inhibitor and an Aromatase Inhibitor: An FDA Pooled Analysis

Lynn J. Howie,Harpreet Singh,Erik Bloomquist,S. B. Wedam,Laleh Amiri-Kordestani,Shenghui Tang,Rajeshwari Sridhara,Jacqueline Sanchez,Tatiana M. Prowell,Paul G. Kluetz,Belinda L. King-Kallimanis,Jennifer J Gao,Amna Ibrahim,Kirsten B. Goldberg,Marc Robert Theoret,Richard Pazdur,Julia A. Beaver

Outcomes of Older Women With Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor–Negative Metastatic Breast Cancer Treated With a CDK4/6 Inhibitor and an Aromatase Inhibitor: An FDA Pooled Analysis

2019

Lynn J. Howie
Harpreet Singh
Erik Bloomquist
S. B. Wedam
Laleh Amiri-Kordestani
Shenghui Tang
Rajeshwari Sridhara
Jacqueline Sanchez
Tatiana M. Prowell
Paul G. Kluetz
Belinda L. King-Kallimanis
Jennifer J Gao
Amna Ibrahim
Kirsten B. Goldberg
Marc Robert Theoret
Richard Pazdur
Julia A. Beaver

PURPOSEMany older women will be treated with a cyclin-dependent kinase 4/6 (CDK4/6) inhibitor and an aromatase inhibitor (AI), given US Food and Drug Administration approval of three agents in this...

Keywords:

Human epidermal growth factor
Hormone receptor
Cancer research
Pathology
Metastatic breast cancer
Kinase
Aromatase inhibitor
Medicine
Drug
Receptor
Oncology
Progression-free survival
pooled analysis
human epidermal growth factor receptor
Internal medicine

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations